RFK Jr. Pushes FDA to Ease Enforcement on Unproven Peptides

The Food and Drug Administration has sent the White House an "Interim Access Policy" that would let the agency stop enforcing current restrictions on a dozen unproven peptide drugs, according to people familiar with the proposal cited by The Associated Press and reported by Ars Technica. The filing notice appears on an Office of Management and Budget website but does not disclose the policy's text, the AP's sources told Ars Technica.

What would the FDA's "enforcement discretion" actually do?

Under the proposal, the FDA would decline to enforce existing restrictions on certain peptide drugs, giving specialty compounding pharmacies — which mix customized drug formulas — assurance they will not be targeted for making the products, people familiar with the plan told the AP, per Ars Technica. The move would not formally relegalize the peptides; it would simply mean the agency looks past current rules while a separate review continues.

Why did FDA scientists object to these specific peptides?

In 2023, FDA staff scientists concluded a dozen injectable peptides lacked sufficient data on safety and efficacy and posed risks, prompting their removal from the list of drugs compounding pharmacies may legally produce, Ars Technica reported. That staff finding has not changed: scientists who reviewed the drugs again this year maintained the same position, even as an outside advisory panel moved in the opposite direction.

How did a conflicted panel end up reviewing the drugs?

The FDA announced in April it would reconsider the 12 peptides. In June, Secretary Kennedy appointed nine new members to the 13-person advisory panel; at least six of them have ties to peptide-related businesses or clinics, a conflict-of-interest issue Ars Technica flagged directly. In July, that panel voted to recommend returning six of the first seven peptides it reviewed to the compounding list — overruling the FDA's own staff scientists.

Why do MAHA-aligned sellers want peptides back on the market?

Sellers market the peptides, without supporting evidence, as able to improve appearance, boost energy, or speed injury recovery, according to Ars Technica. Kennedy has called himself a "big fan" of peptides and pledged to end what he termed "FDA's war" on them after taking office, the outlet reported.

By the numbers

• 12 peptide drugs under renewed FDA review after being stricken from the compounding list in 2023.
• 9 of 13 advisory panel seats filled by Kennedy appointees in June, at least six with peptide-industry ties.
• 6 of 7 peptides the panel recommended reinstating at its July meeting.

What to watch

• Whether the White House clears the Interim Access Policy and how quickly HHS acts once it does.
• Whether the FDA begins the formal rulemaking needed to permanently return peptides to the compounding list — a process the AP notes could take years.
• Whether compounding pharmacies ramp up peptide production once enforcement discretion, if finalized, takes effect.
• Any public comment from HHS, which did not respond to Ars Technica's request for comment on the proposal.